Abraxane and gemcitabine, risk of febrile neutropenia – pro
The guidelines require a risk fo 20% of febrile neutropenia to support G-CSF drugs, like Zarxio. The risk of the current regimen is less. Courtney et al reported that febrile neutropenia was reported in 1% to 8% of patients in the studies that were reviewed. Neutropenia, but not febrile neutropenia appears to be 23% in another review of studies by Blomstrand.
Porter CE, Waddell JA, Solimando DA Jr. nab-Paclitaxel Plus Gemcitabine Regimen for Pancreatic Cancer. Hosp Pharm. 2014;49(1):18-22. doi:10.1310/hpj4901-18
Blomstrand H, Scheibling U, Bratthäll C, Green H, Elander NO. Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. BMC Cancer. 2019;19(1):40. Published 2019 Jan 8. doi:10.1186/s12885-018-5244-2